Haleon HLN
NYSE HLN
$9.89 +0.02 (+0.15%)
At close: Aug 20, 2026 · 11:04 AM UTC

Haleon (HLN) Non Operating Interest Expenses (2021 - 2025)

Haleon's (HLN) quarterly Non Operating Interest Expenses came in at -$235.8 million in Q4 2025, up 36.46% on a QoQ basis from -$371.1 million in Q4 2023.

Haleon (HLN) Non Operating Interest Expenses (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Non Operating Interest Expenses data on file, last reported at -$235.8 million in Q4 2025.

  • Quarterly Non Operating Interest Expenses changed N/A year-over-year to -$235.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$878.2 million (changed N/A YoY) and the FY2024 annual result came in at -$490.9 million, up 1.83% from the prior year.
  • Non Operating Interest Expenses improved to -$235.8 million in Q4 2025, from -$371.1 million in the prior quarter.
  • In the past five years, Non Operating Interest Expenses ranged from a high of -$18.9 million in Q4 2021 to a low of -$371.1 million in Q4 2023.
  • A 4-year average of -$155.3 million and a median of -$116.2 million in 2023 frame the typical range for Non Operating Interest Expenses.
  • Annual changes were most pronounced in 2022 — Non Operating Interest Expenses plunged 391.0% — and 2023, when it plunged 300.5%.
  • Tracing HLN's Non Operating Interest Expenses over 4 years: stood at -$18.9 million in 2021, then sank by 391.0% to -$92.7 million in 2022, then plunged by 300.5% to -$371.1 million in 2023, then jumped by 36.46% to -$235.8 million in 2025.
  • The last three Non Operating Interest Expenses figures came in at -$235.8 million (Q4 2025), -$371.1 million (Q4 2023), and -$155.2 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Haleon 43.85 Bn 42.88 Bn - -
2 Teva Pharmaceutical Industries 43.31 Bn 39.66 Bn 2.15 Bn -
3 Zoetis 31.65 Bn 29.98 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.68 Bn 22.88 Bn 5.10 Bn -400.56 Mn
5 United Therapeutics 22.18 Bn 19.52 Bn 683.80 Mn 2.90 Mn
6 Viatris 18.82 Bn 17.94 Bn 1.46 Bn 120.70 Mn
7 Neurocrine Biosciences 15.70 Bn 15.31 Bn 935.80 Mn 2.90 Mn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.13 Bn 9.96 Bn - -
10 Alkermes 8.21 Bn 7.55 Bn 397.90 Mn 25.93 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -235.81 Mn
Dec 31, 2023 -371.10 Mn
Jun 30, 2023 -155.17 Mn
May 3, 2023 -116.16 Mn
Dec 31, 2022 -92.66 Mn
Sep 20, 2022 -97.27 Mn
Dec 31, 2021 -18.87 Mn